What’s New and What’s Next in CLL

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO

Recorded on January 27, 2026

Brad Kahl, MD
Professor of Medicine
Division of Oncology, Department of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, MO
In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion!

Additional Blood Cancer United Resources:

• Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
• Blood Cancer United Resources for Patients